Reference
Compare stacks
Every combination in the file, field by field. The table records differences in what is documented — it does not rank the combinations or score them.
| Field | BPC-157 + TB-500 (the “Wolverine” blend) | CJC-1295 + Ipamorelin | Cagrilintide + Semaglutide | Selank + Semax | GHK-Cu in cosmetic combinations | GHK-Cu + BPC-157 + TB-500 (“GLOW”) | GHK-Cu + BPC-157 + TB-500 + KPV (“KLOW”) |
|---|---|---|---|---|---|---|---|
| Compounds | |||||||
| Why discussed | Discussed as a pairing of two compounds with connective-tissue research histories — BPC-157 for tendon, ligament, gut and muscle models; TB-500 as a fragment of thymosin β4, whose full-length parent has wound-healing literature. The pairing rationale is that the mechanisms are complementary; the sources that say this are overwhelmingly community and vendor material, not trials.. | Discussed as a GHRH-analogue plus GH-secretagogue pairing intended to stimulate GH release through two pathways at once — the “synthetic GH axis” pairing. The rationale appears in vendor and community material; the pharmacology of each pathway is real, but the pairing itself was not studied in the indexed literature.. | An investigational amylin analogue combined with an approved GLP-1 receptor agonist in a sponsor's Phase 3 programme for weight management — the rare pairing where the combination itself is genuinely under study.. | Two Russian-developed heptapeptides discussed together for cognition, anxiety and focus. Semax is a registered product in some jurisdictions; Selank is not. | Copper tripeptide-1 appears in topical formulations alongside matrix-support ingredients (retinoids, niacinamide, other signal peptides). Cosmetic formulation is a different regulatory world from injectable use — the FDA compounding entry for injectable GHK-Cu was withdrawn, while topical INCI use is a normal cosmetic-ingredient path.. | Sold under the community name “GLOW” as a skin-and-repair combination: a copper peptide associated with cosmetic collagen research, plus two compounds with preclinical wound-healing literature. The rationale is mechanistic storytelling, not a studied protocol, and vendor constituent lists for products using this name are not consistent.. | Marketed as an extended “GLOW” blend with KPV added for its proposed anti-inflammatory activity. Four unapproved compounds are being combined on the basis of separate laboratory mechanisms, not a combination study. |
| Evidence for the combination | Components indexed separately | Components indexed separately | Combination registered as a trial | Community-reported only | Discussed in published sources | Community-reported only | Community-reported only |
| Components with human evidence | 1 of 2 | 2 of 2 | 2 of 2 | 0 of 2 | 0 of 1 | 1 of 3 | 1 of 4 |
| Community protocol discussion | Yes — labelled community-reported | Yes — labelled community-reported | — | Yes — labelled community-reported | — | — | — |
| Strongest source level on file | Peer-reviewed (components only) | Peer-reviewed (components only) | Official (registry) | Community only | Peer-reviewed (narrative) | Community only | Community only |
| Documented concerns | 3 recorded · detail | 3 recorded · detail | 2 recorded · detail | 2 recorded · detail | 1 recorded · detail | 4 recorded · detail | 4 recorded · detail |
A stack with stronger sources is not a better stack — the support labels describe what exists in the documentary record, which is different from what works. Where the label says Components indexed separately or Community-reported only, nobody has indexed evidence that the combination itself does what the discussion assumes.